바이오스펙테이터

바이오스펙테이터 Jongwon jang 기자

PH Pharma is a domestic company that is currently developing new drugs. It was founded in 2015 by President Heo Ho-yeong, who had been working to develop new drugs for global markets. President Heo Ho-yeong was deeply involved in 10 major M&As and IPOs, including the M&A of BiPar Science and Sanofi, and the IPOs of CytomX, Geron, and Nektar Therapeutics.

In the fourth year since its startup, PH Pharma is now consolidating its business strategy, which consists of the introduction of prospective candidate materials for new drugs from global companies, development of new drugs thereof in a short period of time, and transference of the technologies of new drugs to other companies. The company has completed the 2b phase clinical trial for the therapeutics for glaucoma, the ‘PHP-201’; and currently has the 1b-phase clinical trial in the U.S.A. in progress for the therapeutics for non-alcoholic steatohepatitis. The two materials, put into the development of new drugs, were imported from Germany (Bayer) and Belgium (Amakem), respectively.

PH Pharma appointed Kim Jae-sik as the Chief Financial and Chief Executive Officer, who was previously a Head of Business Administration and the Planning Division of Daewoong Pharmaceutical Co., Ltd., and Chief Financial Officer of Hanmi Science Co., Ltd. President Kim introduced the company with, “... PH Pharma is characterized by the strongest pipeline platform technology, and the people therein.”

① PHP-201: Rhokinase Suppression Mechanism, Suppression of Glaucoma by Relaxation of the Outlet of Aqueous Humor...